Cosentyx®
Secukinumab is a fully human anti-IL-17A monoclonal antibody for psoriasis and spondyloarthropathies. Targets the IL-17 pathway central to these conditions.
| Dosage Form | SC Injectable (Prefilled Syringe / Pen / Lyophilized Powder) |
| Strength | 150 mg/mL |
| Storage | Store at 2–8°C. Do not freeze. Protect from light. |
| Category | Immunology |
| Availability | Available for Transfer |
Plaque psoriasis (moderate-to-severe); psoriatic arthritis; ankylosing spondylitis; non-radiographic axial spondyloarthritis; enthesitis-related arthritis.
Selectively binds to IL-17A, preventing its interaction with the IL-17 receptor. Inhibits release of pro-inflammatory cytokines and chemokines, reducing inflammation in skin and joints.
Each Burrard Pharmaceuticals technology transfer package for Secukinumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.